“…Also, two independent GPI-APs (CD59 and GFP) could be associated with a lentiviral vector simultaneously ( 18 ). While these approaches were mostly targeted at facilitating gene therapy using VVs ( 18 , 29 , 55 , 89 , 90 ), recently strategies for the use in vaccination were suggested ( 19 , 36 , 51 , 91 , 92 ). In these studies, influenza VLPs were generated in a recombinant baculovirus system ( 93 , 94 ) and modified, on one hand, with either GPI-anchored IL12, GM-CSF, or ICAM-1 (collectively termed GPI immunostimulatory molecules) as adjuvant agents in anti-viral immune responses ( 19 ) and, on the other hand, with GPI-HER2 as a model for protein transfer of a tumor-associated antigen for tumor vaccination ( 36 ).…”